The contemporary pharmacological management of overactive bladder

BJOG: An International Journal of Obstetrics and Gynaecology

Volumn 113, Issue SUPPL. 2, 2006, Pages 19-28

  Chapple, C R ^a  

^a SHEFFIELD HALLAM UNIVERSITY   (United Kingdom)

Author keywords

Antimuscarinic therapy; Comparative studies; Overactive bladder; Pharmacotherapy; Urgency

Indexed keywords

ALFUZOSIN; ATROPINE; BOTULINUM TOXIN; CALCIUM ANTAGONIST; CLENBUTEROL; DARIFENACIN; DESMOPRESSIN; DICYCLOVERINE; DOXAZOSIN; DRUG METABOLITE; FLAVOXATE; FLURBIPROFEN; HYOSCYAMINE; IMIPRAMINE; INDOMETACIN; N DESETHYLOXYBUTYNIN; OXYBUTYNIN; PLACEBO; POTASSIUM CHANNEL STIMULATING AGENT; PRAZOSIN; PROPANTHELINE BROMIDE; PROPIVERINE; SALBUTAMOL; SOLIFENACIN; TAMSULOSIN; TERAZOSIN; TERBUTALINE; TOLTERODINE; TROSPIUM CHLORIDE; UNINDEXED DRUG;

BEHAVIOR THERAPY; BLURRED VISION; CLINICAL ASSESSMENT; CLINICAL TRIAL; CONSTIPATION; COST EFFECTIVENESS ANALYSIS; DIZZINESS; DOSE RESPONSE; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG ELIMINATION; DRUG FORMULATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG RECEPTOR BINDING; DRUG RELEASE; DRUG USE; DRUG WITHDRAWAL; ERYTHEMA; FIRST PASS EFFECT; GASTROESOPHAGEAL REFLUX; HUMAN; MEDICAL SOCIETY; META ANALYSIS; MICTURITION; MORBIDITY; NOCTURIA; OVERACTIVE BLADDER; PHYSIOTHERAPY; PRIORITY JOURNAL; PRURITUS; QUALITY OF LIFE; REVIEW; SYMPTOMATOLOGY; SYSTEMATIC REVIEW; TREATMENT OUTCOME; URGE INCONTINENCE; URINE RETENTION; XEROSTOMIA;

EID: 33845598415     PISSN: 14700328     EISSN: 14710528     Source Type: Journal    
DOI: 10.1111/j.1471-0528.2006.01083.x     Document Type: Review

References (87)

1. Milsom I, Abrams P, Cardozo L, Roberts RG, Thuroff J, Wein AJ. How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study. BJU Int 2001;87:760-6.
2. Stewart WF, Van Rooyen JB, Cundiff GW, Abrams P, Herzog AR, Corey R, et al. Prevalence and burden of overactive bladder in the United States. World J Urol 2003;20:327-36.
3. Wein AJ, Rovner ES. The overactive bladder: an overview for primary care health providers. Int J Fertil Womens Med 1999;44:56-66.
4. Liberman JN, Hunt TL, Stewart WF, Wein A, Zhou Z, Herzog AR, et al. Health-related quality of life among adults with symptoms of overactive bladder: results from a U.S. community-based survey. Urology 2001;57:1044-50.
5. Coyne KS, Payne C, Bhattacharyya SK, Revicki DA, Thompson C, Corey R, et al. The impact of urinary urgency and frequency on health-related quality of life in overactive bladder: results from a national community survey. Value Health 2004;7:455-63.
6. Chapple CR, Artibani W, Cardozo LD, Castro-Diaz D, Craggs M, Haab F, et al. The role of urinary urgency and its measurement in the overactive bladder symptom syndrome: current concepts and future prospects (Review). BJU Int 2005;95:335-40. (Erratum in: BJU Int 2005;95:924.)
7. Cucchi A, Siracusano S, Guarnaschelli C, Rovereto B. Voiding urgency and detrusor contractility in women with overactive bladders. Neurourol Urodyn 2003;22:223-6.
8. Freeman R, Hill S, Millard R, Slack M, Sutherst J; Tolterodine Study Group. Reduced perception of urgency in treatment of overactive bladder with extended-release tolterodine. Obstet Gynecol 2003;102:605-11.
9. Cardozo L. Efficacy, Safety and Tolerability of Solifenacin Succinate in Symptomatic Patients with Overactive Bladder: Results of a Phase IIa Randomized Clinical Trial. Las Vegas, Nevada: Western Section of the American Urological Association, 2003.
10. Cardozo L, Dixon A. Increased warning time with darifenacin: a new concept in the management of urinary urgency. J Urol 2005;173:1214-18.
11. Dmochowski RR, Heit M, Sand PK. The effect of anticholinergic therapy on urgency severity in patients with overactive bladder: clinical assessment of a newly validated tool. Neurorol Urodynam 2003;22:411.
12. Kobelt G, Kirchberger I, Malone-Lee J. Quality-of life aspects of the overactive bladder and the effect of treatment with tolterodine. BJU Int 1998;83:583-90.
13. O'Conor R, Johannesson M, Hass S, Kobelt-Nguyen G. Urge incontinence: quality of life and patients' valuation of symptom reduction. Pharmacoeconomics 1998;14:531-9.
14. Brown JS, McNaughton KS, Wyman JF, Burgio KL, Harkaway R, Bergner D, et al. Measurement characteristics of a voiding diary for use by men and women with overactive bladder. Urology 2003;61:802-9.
15. Bramble FJ. The treatment of adult enuresis and urge incontinence by enterocystoplasty. Br JUrol 1992;54:693-6.
16. Cartwright PC, Snow BW. Bladder autoaugmentation: early clinical experience. J Urol 1989;142:505-7.
17. Schmidt RA. Advances in genitourinary neurostimulation. Neurosurgery 1986;18:1041-4.
18. Schulte-Baukloh H, Michael T, Schobert J, Stolze T, Knispel HH. Efficacy of botulinum-A toxin in children with detrusor hyperreflexia due to myelomeningocoele: primary results. Urology 2002;59:325-7.
19. Schurch B, Stöhrer M, Kramer G, Schmid DM, Gaul G, Hauri D. Botulinum-A toxin for treating detrusor hyperreflexia in spinal cord injured patients: a new alternative to anticholinergic drugs? Preliminary results. J Urol 2000;164:692-7.
20. Thompson IM, Lauvetz R. Oxybutynin in bladder spasm, neurogenic bladder and enuresis. Urology 1976;8:452.
21. Huggins ME, Bhatia NN, Ostergard DR. Urinary incontinence: newer pharmacotherapeutic trends. Curr Opin Obstet Gynaecol 2003;15:419-27.
22. Nilvebrant L, Andersson KE, Gillberg PG, Stahl M, Sparf B. Tolterodine - a new bladder-selective antimuscarinic agent. Eur J Pharmacol 1997;327:195-207.
23. Appell RA, Chancellor MB, Zobrist RH, Thomas H, Sanders SW. Pharmacokinetics, metabolism, and saliva output during transdermal and extended-release oral oxybutynin administration in healthy subjects. Mayo Clin Proc 2003;78:696-702.
24. Abrams P, Freeman R, Anderstrom C, Mattiasson A. Tolterodine, a new antimuscarinic agent: as effective but better tolerated than oxybutynin in patients with an overactive bladder. Br J Urol 1998;81:801-10.
25. Burgio KL, Locher JL, Goode PS, Hardin JM, McDowell BJ, Dombrowski M, et al. Behavioral vs drug treatment for urge urinary incontinence in older women: a randomised controlled trial. JAMA 1998;280:1995-2000.
26. Drutz HP, Appell RA, Gleason D, Klimberg I, Radomski S. Clinical efficacy and safety of tolterodine compared to oxybutynin and placebo in patients with overactive bladder. Int Urogynecol J Pelvic Floor Dysfunct 1999;10:283-9.
27. Madersbacher H, Halaska M, Voigt R, Alloussi S, Hofner K. A placebo-controlled, multicentre study comparing the tolerability and efficacy of propiverine and oxybutynin in patients with urgency and urge incontinence. BJU Int 1999;84:646-51.
28. Thuroff JW, Bunke B, Ebner A, Faber P, de Geeter P, Hannappel J, et al. Randomised, double-blind, multicenter trial on treatment of frequency, urgency and incontinence related to detrusor hyperactivity: oxybutynin versus propantheline versus placebo. J Urol 1991;145:813-6; discussion 816-17.
29. Ouslander JG. Drug therapy: management of overactive bladder. N Eng J Med 2004;350:786-99.
30. Kelleher CJ, Cardozo LD, Khullar V, Salvatore S. A medium-term analysis of the subjective efficacy of treatment for women with detrusor instability and low bladder compliance. Br J Obstet Gynaecol 1997;104:988-93.
31. Gleason DM, Susset J, White C, Munoz DR, Sand PK. Evaluation of a new once-daily formulation of oxbutynin for the treatment of urinary urge incontinence. Ditropan XL Study Group. Urology 1999;54:420-3.
32. Versi E, Appell R, Mobley D, Patton W, Saltzstein D. Dry mouth with conventional and controlled-release oxybutynin in urinary incontinence. The Ditropan XL Study Group. Obstet Gynecol 2000;95:718-21.
33. Anderson RU, Mobley D, Blank B, Saltzstein D, Susset J, Brown JS. Once daily controlled versus immediate release oxybutynin chloride for urge urinary incontinence. OROS Oxybutynin Study Group. J Urol 1999;161:1809-12.
34. Brendler CB, Radebaugh LC, Mohler JL. Topical oxybutynin chloride for relaxation of dysfunctional bladders. J Urol 1989;141:1350-2.
35. Saito M, Watanabe T, Tabuchi F, Otsubo K, Satoh K, Miyagawa I. Urodynamic effects and safety of modified intravesical oxybutynin chloride in patients with neurogenic detrusor overactivity: 3 years experience. Int J Urol 2004;11:592-6.
36. Amark P, Bussman G, Eksborg S. Follow-up of long-time treatment with intravesical oxybutynin for neurogenic bladder in children. Eur Urol 1998;34:148-53.
37. Kasabian NG, Vlachiotis JD, Lais A, Klumpp B, Kelly MD, Siroky MB, et al. The use of intravesical oxybutynin chloride in patients with detrusor hypertonicity and detrusor hyperreflexia. J Urol 1994;151:944-5.
38. Weese DL, Roskamp DA, Leach GE, Zimmern PE. Intravesical oxybutynin chloride: experience with 42 patients. Urology 1993;41:527-30.
39. Davila GW, Daugherty CA, Sanders SW. A short-term, multicenter, randomised double-blind dose titration study of the efficacy and anticholinergic side effects of transdermal compared to immediate release oral oxybutynin treatment of patients with urge urinary incontinence. J Urol 2001;166:140-5.
40. Dmochowski RR, Davila GW, Zinner NR, Gittelman MC, Saltzstein DR, Lyttle S, et al. Efficacy and safety of transdermal oxybutynin in patients with urge and mixed urinary incontinence. J Urol 2002;168:580-6.
41. Dmochowski RR, Sand PK, Zinner NR, Gittelman MC, Davila GW, Sanders SW. Comparative efficacy and safety of transdermal oxybutynin and oral tolterodine versus placebo in previously treated patients with urge and mixed urinary incontinence. Urology 2003;62:237-42.
42. Madersbacher H, Halaska M, Voigt R, Alloussi S, Hofner K. A placebo-controlled, multicentre study comparing the tolerability and efficacy of propiverine and oxybutynin in patients with urgency and urge incontinence. BJU Int 1999;84:646-51.
43. Appell RA. Clinical efficacy and safety of tolterodine in the treatment of overactive bladder: a pooled analysis. Urology 1997;50(6A Suppl):90-6; discussion 97-9.
44. Van Kerrebroeck P, Kreder K, Jonas U, Zinner N, Wein A, Tolterodine Study Group. Tolterodine once-daily: superior efficacy and tolerability in the treatment of the overactive bladder. Urology 2001;57:414-21.
45. Zinner NR, Mattiasson A, Stanton SL. Efficacy, safety, and tolerability of extended-release once-daily tolterodine treatment for overactive bladder in older versus younger patients. J Am Geriatr Soc 2002;50:799-807.
46. Kreder K, Mayne C, Jonas U. Long-term safety, tolerability and efficacy of extended-release tolterodine in the treatment of overactive bladder. Eur Urol 2002;41:588-95.
47. Kelleher CJ, Reese PR, Pleil AM, Okano GJ. Health-related quality of life of patients receiving extended-release tolterodine for overactive bladder. Am J Manag Care 2002;8(19 Suppl):S608-15.
48. Kelleher CJ, Kreder KJ, Pleil AM, Burgess SM, Reese PR. Long-term health-related quality of life of patients receiving extended-release tolterodine for overactive bladder. Am J Manag Care 2002;8(19 Suppl):S616-30.
49. Landis JR, Kaplan S, Swift S, Versi E. Efficacy of antimuscarinic therapy for overactive bladder with varying degrees of incontinence severity. J Urol 2004;171:752-6.
50. Khullar V, Hill S, Laval KU, Schiotz HA, Jonas U, Versi E. Treatment of urge-predominant mixed urinary incontinence with tolterodine extended release: a randomised, placebo-controlled trial. Urology 2004;64:269-74; discussion 274-5.
51. Todorova A, Vonderheid-Guth B, Dimpfel W. Effects of tolterodine, trospium chloride, and oxybutynin on the central nervous system. J Clin Pharmacol 2001;41:636-44.
52. Cardozo L, Chapple CR, Toozs-Hobson P, Grosse-Freese M, Bulitta M, Lehmacher W, et al. Efficacy of trospium chloride in patients with detrusor instability: a placebo-controlled, randomised, double-blind, multicentre clinical trial. BJU Int 2000;85:659-64.
53. Halaska M, Ralph G, Wiedemann A, Primus G, Ballering-Bruhl B, Hofner K, et al. Controlled, double-blind, multicentre clinical trial to investigate long-term tolerability and efficacy of trospium chloride in patients with detrusor instability. World J Urol 2003;20:392-9.
54. Zinner N, Gittelman M, Harris R, Susset J, Kanelos A, Auerbach S; Trospium Study Group. Trospium chloride improves overactive bladder symptoms: a multicenter phase III trial. J Urol 2004;171:2311-15.
55. Smulders RA, Krauwinkel WJ, Swart PJ, Huang M. Pharmacokinetics and safety of solifenacin succinate in healthy young men. J Clin Pharmacol 2004;44:1023-33.
56. Chapple CR, Arano P, Bosch JL, De Ridder D, Kramer AE, Ridder AM. Solifenacin appears effective and well tolerated in patients with symptomatic idiopathic detrusor overactivity in a placebo- and tolterodine-controlled phase 2 dose-finding study. BJU Int 2004;93:71-7.
57. Chapple CR, Rechberger T, Al-Shukri S, Meffan P, Everaert K, Huang M, et al. Randomised, double-blind placebo- and tolterodine-controlled trial of the once-daily antimuscarinic agent solifenacin in patients with symptomatic overactive bladder. BJU Int 2004;93:303-10.
58. Cardozo L, Lisec M, Millard R, van Vierssen Trip O, Kuzmin I, et al. Randomized, double-blind placebo controlled trial of the once daily antimuscarinic agent solifenacin succinate in patients with overactive bladder. J Urol 2004;172:1919-24.
59. Haab F, Cardozo L, Chapple C, Ridder AM; For the Solifenacin Study Group. Long-term open-label solifnacin treatment associated with persisitence with therapy in patients with overactive bladder syndrome. Eur Urol 2005;47:376-84.
60. Kelleher CJ, Cardozo L, Chapple CR, Haab F, Ridder AM. Improved quality of life in patients with overactive bladder symptoms treated with solifenacin. BJU Int 2005;95:81-5.
61. Napier C, Gupta P. Darifenacin is selective for the human recombinant M3 receptor subtype. Neurourol Urodyn 2002;21:A445.
62. Beaumont KC, Cussans NJ, Nichols DJ, Smith DA. Pharmacokinetics and metabolism of darifenacin in the mouse, rat, dog and man. Xenobiotica 1998;28:63-75.
63. Chapple CR, Abrams P. Comparison of darifenacin and oxybutynin in patients with overactive bladder: assessment of ambulatory urodynamics and impact on salivary flow. Eur Urol 2005;48:102-9.
64. Chapple C, Steers W, Norton P, Millard R, Kralidis G, Glavind K, et al. A pooled analysis of three phase III studies to investigate the efficacy, tolerability and safety of darifenacin, a muscarinic M3 selective receptor antagonist, in the treatment of overactive bladder. BJU Int 2005;95:993-1001.
65. Foote J, Glavind K, Kralidis G, Wyndaele JJ. Treatment of overactive bladder in the older patient: pooled analysis of three phase III studies of darifenacin, an M(3) selective receptor antagonist. Eur Urol 2005 (in press).
66. Andersson K-E. Potential benefits of muscarinic M3 receptor selectivity. Eur Urol Suppl 2002;1:23-8.
67. Steers W, Corcos J, Foote J, Kralidis G. An investigation of dose titration with darifenacin, an M3-selective receptor antagonist. BJU Int 2005;95:580-6. (Erratum in: BJU Int 2005;95:1385-6.)
68. Andersson K-E, Appell R, Cardozo L, Chapple C, Drutz H, Fourcroy J, et al. Pharmacological treatment of urinary incontinence. In: Abrams P, Cardozo L, Khoury S, Wein A, editors. Incontinence, 3rd International Consultation on Incontinence, Vol 2. Paris, France: Health Publication Ltd., 2005. p. 809-55.
69. Herbison P, Hay-Smith J, Ellis G, Moore K. Effectiveness of anticholinergic drugs compared with placebo in the treatment of overactive bladder: systematic review. BMJ 2003;326:841-4.
70. Chapple C, Khullar V, Gabriel Z, Dooley JA. The effects of antimuscarinic treatments in overactive bladder: a systematic review and metaanalysis. Eur Urol 2005;48:5-26.
71. Appell RA, Sand P, Dmochowski R, Anderson R, Zinner N, Lama D, et al. Overactive bladder: Judging Effective Control and Treatment Study Group. Prospective randomised controlled trial of extended-release oxybutynin chloride and tolterodine tartrate in the treatment of overactive bladder: results of the OBJECT study. Mayo Clin Proc 2001;76:358-63.
72. Diokno AC, Appell RA, Sand PK, Dmochowski RR, Gburek BM, Klimberg IW, et al. Prospective, randomised, double-blind study of the efficacy and tolerability of the extended-release formulations of oxybutynin and tolterodine for overactive bladder: results of the OPERA trial. Mayo Clin Proc 2003;78:687-95.
73. Sand PK, Miklos J, Ritter H, Appell R. A comparison of extended-release oxybutynin and tolterodine for treatment of overactive bladder in women. Int Urogynecol J Pelvic Floor Dysfunct 2004;15:243-8.
74. Homma Y, Kawabe K. Health-related quality of life of Japanese patients with overactive bladder treated with extended-release tolterodine or immediate-release oxybutynin: a randomized, placebocontrolled trial. World J Urol 2004;22:251-6.
75. Hughes DA, Dubois D. Cost-effectiveness analysis of extended-release formulations of oxybutynin and tolterodine for the management of urge incontinence. Pharmacoeconomics 2004;22:1047-59.
76. Chapple CR, Martinez-Garcia R, Selvaggi L, Toozs-Hobson P, Warnack W, Drogendijk T, et al. A comparison of the efficacy and tolerability of solifenacin succinate and extended release tolterodine at treating overactive bladder syndrome: results of the STAR trial. Eur Urol 2005;48:464-70.
77. Milsom I, Abrams P, Cardozo L, Roberts RG, Thuroff J, Wein AJ. How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study. BJU Int 2001;87:760-6.
78. Van Kerrebroeck P, Kreder K, Jonas U, Zinner N, Wein A. Tolterodine once-daily: superior efficacy and tolerability in the treatment of the overactive bladder. Urology 2001;57:414-21.
79. Cardozo L. Randomized, double-blind placebo-controlled trial of once-daily antimuscarinic agent solifenacin succinate in patients with overactive bladder. J Urol 2004;172:1919-24.
80. Donovan J, Badia X, Corcos J, Gotoh M, Kelleher C, Naughton M, et al. Symptom and quality of life assessment. In: Abrams P, Cardozo L, Khoury S, Wein A, editors. Incontinence. Plymouth, UK: Plymbridge Distributors Ltd., 2002.
81. Mattiasson A, Djurhuus JC, Fonda D, Lose G, Nordling J, Stohrer M. Standardization of outcome studies in patients with lower urinary tract dysfunction: a report on general principles from the Standardisation Committee of the International Continence Society. Neurourol Urodyn 1998;17:249-53.
82. Ushiroyama T, Ikeda A, Ueki M. Clinical efficacy of clenbuterol and propiverine in menopausal women with urinary incontinence: improvement in quality of life. J Med 2000;31:311-19.
83. Burgio KL, Locher JL, Roth DL, Goode PS. Psychological improvements associated with behavioral and drug treatment of urge incontinence in older women. J Gerontol B Psychol Sci Soc Sci 2001;56:46-51.
84. Kelleher CJ, Reese PR, Pleil AM, Okano GJ. Health-related quality of life of patients receiving extended-release tolterodine for overactive bladder. Am J Manag Care 2002;8:S608-15.
85. Homma Y, Kawabe K. Health-related quality of life of Japanese patients with overactive bladder treated with extended-release tolterodine or immediate-release oxybutynin: a randomized, placebo-controlled trial. World J Urol 2004;22:251-56.
86. Zinner N, Gittelman M, Harris R, Susset J, Kanelos A, Auerbach S, et al. Trospium chloride improves overactive bladder symptoms: a multicenter phase III trial. J Urol 2004;171:2311-15, quiz 2435.
87. Kelleher CJ, Cardozo L, Chapple CR, Haab F, Ridder AM. Improved quality of life in patients with overactive bladder symptoms treated with solifenacin. BJU Int 2005;95:81-85.